Trial Profile
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab (Primary) ; Atezolizumab; Ipilimumab
- Indications Solid tumours
- Focus Therapeutic Use
- 14 Feb 2020 Planned End Date changed from 1 Nov 2021 to 1 Nov 2033.
- 14 Feb 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2033.
- 04 Dec 2019 Arms and interventions, indication, phase has been amended.